Randomized Clinical Trial of Sevelamer Carbonate on Serum Klotho and Fibroblast Growth Factor 23 in CKD | Zendy

Sophie Liabeuf | Zendy; JeanPhilippe Ryckelynck | Zendy; N. El Esper | Zendy; Pablo Ureña | Zendy; Christian Combe | Zendy; Bertrand Dussol | Zendy; Denis Fouque | Zendy; Philippe Vanhille | Zendy; Luc Frimat | Zendy; Éric Thervet | Zendy; Romuald Mentaverri | Zendy; Dominique Prié | Zendy; Gabriel Choukroun | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Randomized Clinical Trial of Sevelamer Carbonate on Serum Klotho and Fibroblast Growth Factor 23 in CKD

Author(s) -

Sophie Liabeuf,

JeanPhilippe Ryckelynck,

N. El Esper,

Pablo Ureña,

Christian Combe,

Bertrand Dussol,

Denis Fouque,

Philippe Vanhille,

Luc Frimat,

Éric Thervet,

Romuald Mentaverri,

Dominique Prié,

Gabriel Choukroun

Publication year - 2017

Publication title -

clinical journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.755

H-Index - 151

eISSN - 1555-905X

pISSN - 1555-9041

DOI - 10.2215/cjn.03030317

Subject(s) - medicine , sevelamer , fibroblast growth factor 23 , interquartile range , endocrinology , gastroenterology , randomization , placebo , urology , renal function , creatinine , phosphate binder , randomized controlled trial , kidney disease , hyperphosphatemia , parathyroid hormone , calcium , pathology , alternative medicine

Epidemiologic studies suggest that higher serum phosphaturic hormone fibroblast growth factor 23 levels are associated with increase morbidity and mortality. The aim of the FGF23 Reduction Efficacy of a New Phosphate Binder in CKD Trial was to evaluate the effect of sevelamer carbonate on serum C-terminal fibroblast growth factor 23 levels in normophosphatemic patients with CKD stage 3b/4.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research